This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sitagliptin
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Sitagliptin/Sitagliptin/1" align="right" caption="Sitagliptin, better known as Januvia, ([[1x70]])"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Sitagliptin/Sitagliptin/1" align="right" caption="Sitagliptin, better known as Januvia, ([[1x70]])"/> | ||
===Better Known as: Januvia=== | ===Better Known as: Januvia=== | ||
| - | * Marketed By: | + | * Marketed By: Merck & Co. |
| - | * Major Indication: | + | * Major Indication: [[Hyperglycemia & Type II Diabetes]] |
| - | * Drug Class: | + | * Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor |
| - | * Date of FDA Approval (Patent Expiration): | + | * Date of FDA Approval (Patent Expiration): 2006 (2017) |
| - | * 2009 Sales: | + | * 2009 Sales: $2.4 Billion |
* Importance: | * Importance: | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
Revision as of 10:48, 13 December 2010
|
Better Known as: Januvia
- Marketed By: Merck & Co.
- Major Indication: Hyperglycemia & Type II Diabetes
- Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
- Date of FDA Approval (Patent Expiration): 2006 (2017)
- 2009 Sales: $2.4 Billion
- Importance:
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For Pharmacokinetic Data References, see: References |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
References
